Ainos, Inc. (AIMDW) Stock Price & Analysis
Ainos, Inc. (AIMDW) rose 0.00% to USD 0.13 as of June 10, 2026 at 09:23 UTC, according to Nexqual real-time market data.
AIMDW last closed at USD 0.13; the session ranged USD 0.1–0.13 on volume of 100 shares. Market capitalization is —, with a 52-week range of USD 0.1–0.13 (NCM). Source: Nexqual, June 10, 2026 at 09:23 UTC.
Key Statistics (as of June 10, 2026 at 09:23 UTC)
| Price | USD 0.13 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0.13 |
| Open | USD 0.17 |
| Day Range | USD 0.1 – 0.13 |
| 52-Week Range | USD 0.1 – 0.13 |
| Volume | 100 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (AIMDW)
Nexqual's technical model rates AIMDW "NEUTRAL" based on 3 bullish and 4 bearish signals across 66 daily candles, as of June 10, 2026 at 09:23 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0.1) |
| MACD | -0 (negative) |
Analyst Ratings (AIMDW)
Wall Street analysts rate AIMDW "None", per Nexqual as of June 10, 2026 at 09:23 UTC.
| Consensus Rating | None |
|---|
Earnings (AIMDW)
Source: Nexqual, June 10, 2026 at 09:23 UTC.
Financials & Fundamentals (AIMDW)
| Total Revenue | $18,111 |
|---|---|
| Revenue Growth (YoY) | -99.80% |
| Gross Margin | +79.15% |
| Operating Margin | -1418414.30% |
| Profit Margin | +0.00% |
| ROE | -148.24% |
| Debt / Equity | 242.68 |
| Current Ratio | 0.56 |
| Total Cash | $2.84M |
| Total Debt | $13.81M |
| Free Cash Flow | $616,062 |
Source: Nexqual, June 10, 2026 at 09:23 UTC.
Financial Health Score (AIMDW)
Nexqual rates Ainos, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:23 UTC.
| Growth | Critical — Revenue -100% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — $3M cash vs $14M debt |
| Cash Flow | Strong — FCF $616K, 460% margin |
| Efficiency | Critical — ROE -148%, ROA -33.8% |
Ownership (AIMDW)
| Float | 2.39M |
|---|
Source: Nexqual, June 10, 2026 at 09:23 UTC.
Leadership (AIMDW)
Ainos, Inc. is led by Chun-Hsien Tsai (age 55), CEO, President & Chairman of the Board, per Nexqual as of June 10, 2026 at 09:23 UTC.
| CEO, President & Chairman of the Board | Chun-Hsien Tsai (age 55) |
|---|---|
| Chief Financial Officer | Hsin-Liang Lee (age 54) |
| Director of Corporate Developoment | Chih-Heng Lu (age 45) |
Major Backers & Investors (AIMDW)
Notable institutional backers of Ainos, Inc. include Heights Capital Management, Inc , Boothbay Fund Management, LLC, Clear Street Group Inc., according to Nexqual as of June 10, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Heights Capital Management, Inc | 7.16% |
| Boothbay Fund Management, LLC | 3.21% |
| Clear Street Group Inc. | 1.42% |
Source: Nexqual, June 10, 2026 at 09:23 UTC.
From Ainos, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)
Key Strengths & Strategy (as disclosed to the SEC)
- Ltd. and its Taiwan subsidiary, Taiwan Inabata Sangyo Co., Topco Scientific Co., Ltd., Trusval Technology Co., Ltd., Solomon Technology Corporation, Kenmec Mechanical Engineering Co., Ltd., and Topmed International Biotech Co., Ltd.   Intellectual Property   We seek to protect our technology and competitive position through a combination of patents, trade secrets, proprietary know-how, and other intellectual property rights.
- Our approach emphasizes expanding the role of scent as a machine-readable data modality alongside vision and sound, while maintaining flexibility to address diverse operational requirements.   Separately, we continue to develop VELDONA®, our low-dose oral interferon platform, targeting selected rare, autoimmune, and infectious disease indications.
- We also believe that maintaining operations in Taiwan in the near term enables us to access technical and scientific talent while managing operating costs, supporting the development of high-quality and cost-effective products.   Outsourced Manufacturing.
- We rely on an outsourced manufacturing model, which we believe allows us to manage capital efficiently and maintain operational flexibility.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ACONW | Aclarion, Inc. | USD 0.03 | ▼ 15.36% |
| AIMD | Ainos, Inc. | USD 2.04 | ▲ 4.62% |
| ADXN | Addex Therapeutics Ltd | USD 6.23 | ▲ 6.31% |
| ADGM | Adagio Medical Holdings, Inc | USD 0.75 | ▲ 3.2% |
| ALVOW | Alvotech Warrant | USD 0.3 | ▼ 10.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:23 UTC. This page is informational and not investment advice.